Krystal Biotech

Yahoo Finance • 12 hours ago

High Growth US Tech Stocks To Watch In May 2026

The United States market has experienced a notable upswing, climbing 2.5% in the last week and an impressive 26% over the past year, with earnings expected to grow by 17% annually. In this dynamic environment, identifying high growth tech... Full story

Yahoo Finance • 24 days ago

Here are the major earnings before the open Monday

Major earnings expected before the bell on Monday include: * Norwegian Cruise Line Holdings Ltd. (NCLH [https://seekingalpha.com/symbol/NCLH]) * Tyson Foods (TSN [https://seekingalpha.com/symbol/TSN]) * Axsome Therapeutics (AXSM [ht... Full story

Yahoo Finance • 27 days ago

Krystal Biotech to Present at Upcoming Scientific Conferences

PITTSBURGH, April 30, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the Company will be presenting on multiple programs at upcoming scientific conferences being held in May and June.... Full story

Yahoo Finance • last month

Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026

PITTSBURGH, April 21, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its first quarter 2026 financial results on Monday, May 4, 2026, prior to the open of U.S. markets.... Full story

Yahoo Finance • 2 months ago

Could This Under-the-Radar Healthcare Stock Set You Up for Life?

Krystal Biotech(NASDAQ: KRYS) has risen in prominence in recent years, with its shares gaining over 230% since 2021. Though it remains a mid-cap biotech with only a single marketed compound, it has an exciting pipeline and, if it executes... Full story

Yahoo Finance • 2 months ago

Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services

Palvella Therapeutics Inc. Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (Nasdaq: KRYS), where she helped lead the U.S. launch of VYJUVEK®, supporting its growth f... Full story

Yahoo Finance • 2 months ago

Epidermolysis Bullosa Market Set for Significant Upswing During the Forecast Period (2025-2034) Amid Rising Therapeutic Advancements | DelveInsight

The growth of the epidermolysis bullosa market is expected to be mainly driven by increasing prevalence, patient awareness, label expansion of approved therapies, high cost of therapies, and robust clinical pipeline, including D-Fi/FCX-007... Full story

Yahoo Finance • 3 months ago

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million

On February 17, 2026, Redmile Group disclosed a buy of 4,415,514 Nurix Therapeutics(NASDAQ:NRIX) shares, an estimated $63.43 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commissio... Full story

Yahoo Finance • 3 months ago

Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%

On February 17, 2026, Redmile Group disclosed a buy of 695,000 shares of Immunome(NASDAQ:IMNM), an estimated $12.20 million trade based on quarterly average pricing. What happened According to a February 17, 2026, SEC filing, Redmile Gro... Full story

Yahoo Finance • 3 months ago

Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year

Redmile Group disclosed a significant reduction in its Zymeworks(NASDAQ:ZYME) position in a February 17, 2026, SEC filing, selling an estimated $70.10 million in shares based on quarterly average pricing. What happened According to a Feb... Full story

Yahoo Finance • 3 months ago

Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025

Redmile Group reported a purchase of 16,317 shares of Krystal Biotech(NASDAQ:KRYS) in its February 17, 2026, SEC filing, with the estimated transaction value at $3.43 million based on quarterly average pricing. What happened According to... Full story

Yahoo Finance • 3 months ago

Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26%

Redmile Group disclosed a buy of 1,316,390 shares of Scholar Rock Holding Corporation(NASDAQ:SRRK) in a February 17, 2026, SEC filing, with the estimated transaction value at $49.37 million based on quarterly average pricing. What happene... Full story

Yahoo Finance • 3 months ago

Krystal Biotech, Inc. Q4 2025 Earnings Call Summary

Krystal Biotech, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Execution and Global Commercial Scaling Management attributed Q4 performance to successful US sales force expansion and initial revenue contributions from early launche... Full story

Yahoo Finance • 3 months ago

Here are the major earnings before the open Tuesday

Major earnings expected before the bell on Tuesday include: * Energy Transfer LP (ET [https://seekingalpha.com/symbol/ET]) * Medtronic plc (MDT [https://seekingalpha.com/symbol/MDT]) * Eagle Point Credit Company (ECC [https://seekin... Full story

Yahoo Finance • 3 months ago

Got $300? 2 Biotech Stocks to Buy and Hold Forever

Krystal Biotech(NASDAQ: KRYS) and ARS Pharmaceuticals(NASDAQ: SPRY) have been gaining a lot of attention over the past year, thanks to the potential in their groundbreaking -- and for now, only -- commercial therapies. In 2023, Krystal pi... Full story

Yahoo Finance • 3 months ago

Netflix Is Casting a Light on a Rare Disease. Pearl Jam’s Frontman Is Raising Cash to Cure It.

An organization started by Pearl Jam frontman Eddie Vedder and his wife, Jill, is using venture philanthropy to finance a cure for a rare genetic skin disease. Continue Reading... Full story

Yahoo Finance • 3 months ago

Soleus Adds a Significant Number of Celcuity Shares

Key Points Soleus increased its Celcuity stake by 629,398 shares. The firm held over 1.8 million shares at the end of the quarter. Celcuity now accounts for 6.7% of fund AUM10 stocks we like better than Celcuity › On Feb. 12, Soleus Capi... Full story

Yahoo Finance • 3 months ago

Biotech Stock Nears Entry After FDA News; Earnings On Horizon

Krystal Biotech is engaged in developing genetic medicines. The biotech stock is near a buy point with earnings due soon. Continue Reading... Full story

Yahoo Finance • 3 months ago

Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

PITTSBURGH, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026, prior to the op... Full story

Yahoo Finance • 5 months ago

Why a Fund Placed a $13 Million Bet on Ambarella Stock Before a 20% Post-Earnings Drop

Key Points New York City-based S Squared Capital increased its Ambarella holding by 35,000 shares in the third quarter. The overall value of the position increased by about $4.8 million. As of quarter-end, the fund reported holding 153,55... Full story